Making Better CAR-T Cells to Fight Lymphoma
This patent describes a specific way to prepare anti-CD19 CAR-T cell therapy for lymphoma patients, by increasing the number of certain "naïve" T cells to improve treatment success and reduce side effects.
Patent Number
US 12630603
Status
Active
Filing Date
February 20, 2021
Grant Date
May 19, 2026
Expiration
February 20, 2041
Claims
15
Assignee
Kite Pharma
Inventors
John Rossi, Jenny Jiyun Kim, Adrian Bot, William GO, Vicki Plaks, Szu-Ting CHOU
Citations
0 forward · 8 backward
What it covers
The patent claims a method for making an anti-CD19 Chimeric Antigen Receptor (CAR)-T cell immunotherapy product that works better and has fewer severe side effects for Non-Hodgkin's Lymphoma (NHL) patients. It involves taking a patient's T cells and, during the manufacturing process, specifically increasing or maximizing the percentage of "naïve" CD4+ and CD8+ T cells, identified by the CD45RA+ CCR7+ markers (Claim 1). This optimized product must contain at least 20x10^6 of these specific naïve T cells, adjusted for the patient's tumor size (Claim 1). For example, a patient with relapsed/refractory large B-cell lymphoma (Claim 3) would receive a CAR-T infusion engineered with a higher proportion of these specific T cells, aiming for a more lasting response and less severe cytokine release syndrome or neurological issues (Claim 1).
What it doesn't cover
- —Does not cover CAR-T cell therapies that do not specifically increase or maximize the percentage of CD4+ and CD8+ T cells with a CD45RA+ CCR7+ naïve phenotype (Claim 1).
- —Does not cover CAR-T cell manufacturing methods that do not ensure at least 20x10^6 of these specific naïve T cells in the final product (Claim 1).
- —Does not cover CAR-T cell therapies targeting antigens other than CD19 (Claim 1).
- —Does not cover CAR-T cell therapies for cancers other than Non-Hodgkin's Lymphoma, advanced-stage indolent NHL, large B-cell lymphoma, or Mantle Cell Lymphoma (Claim 3).
- —Does not cover methods of simply administering CAR-T cells without a specific manufacturing step to enrich for naïve T cells.
The clever bit
The clever bit is recognizing that not all T cells are equally effective in CAR-T therapy, and that enriching for a specific "naïve" T cell phenotype (CD45RA+ CCR7+) during manufacturing can lead to both better, more lasting cancer responses and fewer severe side effects like cytokine release syndrome.
Why it matters
Chimeric Antigen Receptor (CAR)-T cell therapy is a powerful, personalized treatment for certain blood cancers, but it can have severe side effects and not all patients respond durably. This patent addresses these challenges by proposing a manufacturing method to create a more effective and safer CAR-T product. By focusing on specific T cell types, it aims to improve patient outcomes, making this advanced therapy more widely applicable and tolerable.
Real-world examples
- 1.Yescarta (axicabtagene ciloleucel)
- 2.Tecartus (brexucabtagene autoleucel)
- 3.Other anti-CD19 CAR-T cell therapies
- 4.Personalized cancer immunotherapies
Generated by PatentBrief · Not legal advice · patentbrief.org
US 12630603 · 2026